Stockreport

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Enveric Biosciences, Inc.  (ENVB) 
PDF Prioritized EB-003 as lead development candidate. EB-003 is a novel, non-hallucinogenic neuroplastogenic molecule designed to treat severe mental health disordersAnnounc [Read more]